Physician profile
Leonid Shunyakov
NPI 1396709895
$2,086,589.61
in general payments reported to CMS, 2019-2025
97 companies · $389K in 2025
The $389K reported for 2025 was more than what 99% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $325K · 2020: $129K · 2021: $234K · 2022: $334K · 2023: $349K · 2024: $327K · 2025: $389K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $773K · Consulting Fee: $171K · Travel and Lodging: $71K · Food and Beverage: $31K · Honoraria: $19K · Education: $762.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $772,698.57 |
| Consulting Fee | $170,883.83 |
| Travel and Lodging | $70,992.92 |
| Food and Beverage | $30,988.38 |
| Honoraria | $18,590.00 |
| Education | $761.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $359,740.31 | 2019-2025 | Opdivo, Opdualag, Reblozyl |
| Astrazeneca Pharmaceuticals Lp | $249,648.44 | 2019-2025 | Calquence, Enhertu, Imfinzi |
| Janssen Biotech, INC. | $205,836.74 | 2019-2025 | Carvykti, Rybrevant, Tecvayli |
| Abbvie INC. | $118,813.01 | 2019-2025 | Venclexta |
| Seagen INC. | $118,482.58 | 2019-2025 | Tukysa, Padcev |
| Daiichi Sankyo INC. | $107,178.09 | 2021-2025 | Enhertu, Datroway, Injectafer |
| Glaxosmithkline, LLC. | $103,646.80 | 2020-2025 | Ojjaara, Jemperli, Zejula |
| Regeneron Healthcare Solutions, INC. | $88,251.58 | 2021-2025 | Libtayo, Lynozyfic |
| Jazz Pharmaceuticals INC. | $77,035.22 | 2019-2024 | |
| Karyopharm Therapeutics INC. | $52,615.65 | 2020-2023 | Xpovio |
| Beigene USA, INC. | $51,321.08 | 2020-2025 | Brukinsa, Tevimbra |
| Genzyme Corporation | $48,853.66 | 2019-2025 | |
| Genentech USA, INC. | $46,207.78 | 2019-2025 | Tecentriq, Alecensa, Venclexta |
| Exelixis INC. | $42,929.34 | 2019-2025 | Cabometyx |
| Amgen INC. | $40,105.92 | 2019-2025 | Imdelltra (Amg757), Kyprolis, Kyprolis |
Show all 96 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $38,487.59 | 2019-2025 | Tazverik, Onivyde |
| Astellas Pharma US INC | $37,774.65 | 2019-2025 | Padcev, Cresemba, Xospata |
| Merck Sharp & Dohme LLC | $28,378.28 | 2019-2025 | Keytruda |
| Celgene Corporation | $25,767.28 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Epizyme, INC. | $23,906.94 | 2020-2022 | |
| Pfizer INC. | $23,228.21 | 2019-2025 | |
| Beone Medicines USA, INC. | $22,859.14 | 2025 | Tevimbra, Brukinsa |
| Gilead Sciences, INC. | $22,758.53 | 2019-2025 | Trodelvy |
| Genmab U.S., INC. | $17,332.81 | 2024-2025 | Epkinly |
| Janssen Scientific Affairs, LLC | $14,433.37 | 2019-2025 | Imbruvica, Akeega, Rybrevant |
| Mirati Therapeutics, INC. | $13,651.76 | 2023-2024 | Krazati |
| Novartis Pharmaceuticals Corporation | $10,891.94 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $10,798.84 | 2019-2023 | Imbruvica |
| Lilly USA, LLC | $9,914.41 | 2020-2025 | Jaypirca, Retevmo, Verzenio |
| Eisai INC. | $7,111.63 | 2019-2025 | |
| Emd Serono, INC. | $6,888.95 | 2019-2024 | Bavencio |
| Novocure INC. | $6,499.93 | 2023-2025 | Optune, Optune Lua (Novottf-200t) |
| Array Biopharma INC | $6,346.26 | 2019-2025 | Braftovi, Mektovi, Lorbrena |
| Sun Pharmaceutical Industries INC. | $5,390.82 | 2019-2022 | |
| Roche Diagnostics Corporation | $4,919.61 | 2022 | |
| Incyte Corporation | $4,595.61 | 2020-2024 | Monjuvi, Jakafi, Pemazyre |
| Genentech, INC. | $4,562.48 | 2022-2024 | Tecentriq, Columvi, Polivy |
| Syndax Pharmaceuticals, INC. | $4,325.36 | 2025 | Revuforj |
| Johnson & Johnson Health Care Systems INC. | $2,940.00 | 2023 | Darzalex |
| G1 Therapeutics, INC. | $2,815.86 | 2022-2023 | Cosela |
| Tg Therapeutics, INC. | $2,115.00 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $2,039.03 | 2019-2025 | |
| Morphosys, US INC. | $1,920.00 | 2021 | |
| Kite Pharma, INC. | $1,868.33 | 2020-2025 | Yescarta |
| Immunomedics, INC. | $1,575.00 | 2020 | |
| Janssen Global Services, LLC | $1,500.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,473.51 | 2019-2024 | Ninlaro, Fruzaqla, Iclusig |
| Puma Biotechnology, INC. | $1,010.99 | 2020 | |
| Beigene, Ltd. | $975.00 | 2020-2021 | |
| Acceleron Pharma, INC. | $845.00 | 2021 | |
| Eli Lilly and Company | $625.00 | 2021-2025 | |
| Onmark, INC. | $350.00 | 2024 | |
| Rigel Pharmaceuticals, INC. | $319.36 | 2020-2024 | Tavalisse, Rezlidhia |
| Foundation Medicine, INC. | $244.61 | 2019-2023 | |
| Aveo Pharmaceuticals, INC. | $198.32 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $181.98 | 2022 | |
| Medtronic, INC. | $168.76 | 2025 | Osteocool Rf Ablation System |
| Adaptive Biotechnologies Corporation | $133.84 | 2023-2024 | Clonoseq |
| Clovis Oncology, INC. | $120.00 | 2019 | |
| Cti Biopharma Corp. | $117.42 | 2022 | |
| Servier Pharmaceuticals LLC | $109.13 | 2022-2025 | |
| Recordati_rare_diseases_inc. | $107.43 | 2025 | Enjaymo |
| Tempus Ai, INC | $98.54 | 2024 | |
| Tesaro, INC. | $92.23 | 2019 | |
| Progenics Pharmaceuticals, INC. | $84.68 | 2022 | |
| Kyowa Kirin, INC. | $83.55 | 2020-2023 | Poteligeo |
| Sobi, INC | $82.42 | 2022-2025 | |
| Myovant Sciences INC. | $80.68 | 2021-2022 | |
| Acrotech Biopharma INC. | $65.73 | 2021-2022 | |
| Pharmaessentia USA Corporation | $54.89 | 2022-2023 | Besremi |
| Adc Therapeutics America, INC. | $54.35 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.16 | 2023-2024 | Gilotrif |
| Janssen Pharmaceuticals, INC | $46.54 | 2019 | |
| Organon LLC | $41.21 | 2022-2023 | Ontruzant |
| Accord Healthcare, INC. | $36.56 | 2022-2023 | |
| Secura Bio, INC. | $35.18 | 2019 | |
| Alnylam Pharmaceuticals INC. | $34.28 | 2021-2023 | Givlaari |
| Lexicon Pharmaceuticals, INC. | $34.16 | 2019 | |
| Amag Pharmaceuticals, INC. | $31.39 | 2021 | |
| Advanced Accelerator Applications | $31.38 | 2020 | |
| Verity Pharmaceuticals INC. | $29.16 | 2022 | |
| Aurobindo Pharma USA, INC. | $24.94 | 2020 | |
| Dendreon Pharmaceuticals LLC | $22.70 | 2024 | Provenge |
| Pharmacosmos Therapeutics INC. | $22.44 | 2022 | |
| Blue Earth Diagnostics | $21.53 | 2025 | Posluma |
| Coherus Oncology, INC. | $20.61 | 2025 | Loqtorzi |
| Corcept Therapeutics | $19.60 | 2025 | Korlym |
| Iovance Biotherapeutics, INC. | $19.15 | 2024 | Amtagvi |
| Menarini Silicon Biosystems, INC. | $18.54 | 2023 | Cellsearch |
| Springworks Therapeutics, INC. | $18.47 | 2025 | Ogsiveo |
| Azurity Pharmaceuticals, INC. | $17.34 | 2025 | Danziten |
| Mylan Institutional INC. | $16.93 | 2023 | Ogivri, Fulphila |
| Teva Pharmaceuticals USA, INC. | $16.90 | 2019 | |
| Innate Pharma, INC | $14.86 | 2020 | |
| Apellis Pharmaceuticals, INC. | $13.31 | 2023 | Empaveli |
| Agios Pharmaceuticals, INC. | $12.03 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$3,511.38 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonid Shunyakov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.